FAST NEWS: Legend Biotech Plans $250 Million ADS Public Offering
The latest: Genscript Biotech Corp. (1548.HK) announced its New York-listed subsidiary, Legend Biotech Corp. (LEGN.US), plans to conduct a public offering of $250 million worth of American Depository Shares (ADS).…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Forget the pearls and cheese, Chagee says, offering up simpler milk teas for U.S. investors
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
